{
"info": {
"nct_id": "NCT00003731",
"official_title": "First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial",
"inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with at least 25% oligodendroglial elements Recurrent or progressive disease following radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits from the present recurrence No new neurological deficits interfering with daily activities No tumor causing midline shift or brain stem compression due to which a rapid deterioration is to be expected in case of no response No signs of increased intracranial pressure No extracranial disease\n\nPATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignant or nonmalignant diseases interfering with follow-up No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified Other: No other concurrent investigational drugs No other concurrent antitumor agents"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 70 Years",
"criterions": [
{
"exact_snippets": "maximum age of 70 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with at least 25% oligodendroglial elements Recurrent or progressive disease following radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits from the present recurrence No new neurological deficits interfering with daily activities No tumor causing midline shift or brain stem compression due to which a rapid deterioration is to be expected in case of no response No signs of increased intracranial pressure No extracranial disease",
"criterions": [
{
"exact_snippets": "Histologically proven oligodendroglioma or oligoastrocytoma",
"criterion": "histological diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"oligodendroglioma",
"oligoastrocytoma"
]
}
]
},
{
"exact_snippets": "at least 25% oligodendroglial elements",
"criterion": "oligodendroglial elements",
"requirements": [
{
"requirement_type": "percentage",
"expected_value": {
"operator": ">=",
"value": 25,
"unit": "%"
}
}
]
},
{
"exact_snippets": "Recurrent or progressive disease following radiotherapy",
"criterion": "disease status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"recurrent",
"progressive"
]
}
]
},
{
"exact_snippets": "At least 3 months since prior radiotherapy",
"criterion": "time since prior radiotherapy",
"requirements": [
{
"requirement_type": "time elapsed",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Measurable disease by MRI or CT scan",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "assessment method",
"expected_value": [
"MRI",
"CT scan"
]
}
]
},
{
"exact_snippets": "Lesion must have a diameter of at least 1 cm",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "diameter",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "No progressive neurological deficits from the present recurrence",
"criterion": "progressive neurological deficits",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No new neurological deficits interfering with daily activities",
"criterion": "new neurological deficits",
"requirements": [
{
"requirement_type": "interference with daily activities",
"expected_value": false
}
]
},
{
"exact_snippets": "No tumor causing midline shift or brain stem compression",
"criterion": "tumor effects",
"requirements": [
{
"requirement_type": "effects",
"expected_value": [
"no midline shift",
"no brain stem compression"
]
}
]
},
{
"exact_snippets": "No signs of increased intracranial pressure",
"criterion": "increased intracranial pressure",
"requirements": [
{
"requirement_type": "signs",
"expected_value": false
}
]
},
{
"exact_snippets": "No extracranial disease",
"criterion": "extracranial disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignant or nonmalignant diseases interfering with follow-up No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up",
"criterions": [
{
"exact_snippets": "Age: 18 to 70",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 70,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "Performance status: WHO 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "WHO"
}
}
]
},
{
"exact_snippets": "Life expectancy: At least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Neutrophil count at least 1,500/mm3",
"criterion": "neutrophil count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Bilirubin no greater than 1.25 times upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.25,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "AST/ALT no greater than 2 times ULN",
"criterion": "AST/ALT level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Alkaline phosphatase no greater than 2 times ULN",
"criterion": "alkaline phosphatase level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Creatinine clearance at least 60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "clearance",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "mL/min"
}
}
]
},
{
"exact_snippets": "Creatinine no greater than 1.25 times ULN",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.25,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Not pregnant or nursing",
"criterion": "pregnancy/nursing status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "Fertile patients must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "use",
"expected_value": true
}
]
},
{
"exact_snippets": "No other malignant or nonmalignant diseases interfering with follow-up",
"criterion": "interfering diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up",
"criterion": "conditions hampering compliance",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified Other: No other concurrent investigational drugs No other concurrent antitumor agents",
"criterions": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent investigational drugs",
"criterion": "concurrent investigational drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent antitumor agents",
"criterion": "concurrent antitumor agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}